- Home
- GGR vs CRBP Comparison
GGR vs CRBP Comparison
Compare GGR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- CRBP
- Stock Information
- Founded
- GGR 2011
- CRBP 2009
- Country
- GGR Taiwan
- CRBP United States
- Employees
- GGR N/A
- CRBP 19
- Industry
- GGR Auto Manufacturing
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- GGR Consumer Discretionary
- CRBP Health Care
- Exchange
- GGR Nasdaq
- CRBP Nasdaq
- Market Cap
- GGR 166.7M
- CRBP 158.3M
- IPO Year
- GGR N/A
- CRBP N/A
- Fundamental
- Price
- GGR $0.54
- CRBP $13.00
- Analyst Decision
- GGR Hold
- CRBP Strong Buy
- Analyst Count
- GGR 2
- CRBP 8
- Target Price
- GGR $0.50
- CRBP $62.00
- AVG Volume (30 Days)
- GGR 765.6K
- CRBP 313.3K
- Earning Date
- GGR 02-05-2025
- CRBP 11-07-2024
- Dividend Yield
- GGR N/A
- CRBP N/A
- EPS Growth
- GGR N/A
- CRBP N/A
- EPS
- GGR N/A
- CRBP N/A
- Revenue
- GGR $329,041,000.00
- CRBP N/A
- Revenue This Year
- GGR N/A
- CRBP N/A
- Revenue Next Year
- GGR $3.73
- CRBP N/A
- P/E Ratio
- GGR N/A
- CRBP N/A
- Revenue Growth
- GGR N/A
- CRBP N/A
- 52 Week Low
- GGR $0.40
- CRBP $5.25
- 52 Week High
- GGR $2.67
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- GGR 44.28
- CRBP 25.10
- Support Level
- GGR $0.54
- CRBP $12.90
- Resistance Level
- GGR $0.65
- CRBP $16.21
- Average True Range (ATR)
- GGR 0.05
- CRBP 0.95
- MACD
- GGR -0.01
- CRBP -0.16
- Stochastic Oscillator
- GGR 2.08
- CRBP 1.69
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.